Despite the depreciation in the rupee, which tends to help IT exporters, the impact on their operating margins in the third quarter of the 2015 fiscal year will be minimal. Earlier this month, the rupee hit an 8-month low of 62.22 against the US ... Hindu Business Line, 10 hours ago
1 images for "sarabjit kour nangra"
The US Food and Drug Administration (USFDA) has found what it calls nine inspectional observations at Unit VI of Dr Reddy's Laboratories Srikakulam plant. The apex regulator has through Form 483 sought explanation on the nine observations that are ...Financial Express, 1 day ago We maintain neutral stance on Dr Reddy`s: Angel Broking MyIris, 1 day ago Dr Reddy's unit receives US FDA observations on possible lapses Financial Express, 17 hours ago
US health regulator Food and Drug Administration (FDA) has procedural deviations at Dr Reddy's Laboratories manufacturing plant at Srikakulam Hyderabad: US health regulator Food and Drug Administration (FDA) has procedural deviations at Dr ...Deccan Chronicle, 1 day ago DRL Visakhapatnam Plant Gets FDA Fiat on Suspected Lapses New Indian Express, 1 day ago Dr Reddy's plant gets USFDA fiat on suspected lapses Business Standard India, 1 day ago Dr Reddy's Plant Gets FDA Fiat On Suspected Lapses The Freepress Journal, 1 day ago
The pay-for-delay case over heartburn pill Nexium, that Ranbaxy is caught in, is set to go to trial as the judge for Massachusetts Federal court said the case must go before the jury. Buyers of the drug had filed a lawsuit alleging that patent owner ...Financial Chronicle, 2 days ago Angel Broking remains neutral on Ranbaxy MyIris, 2 days ago Lupin joins hands with Merck Serono for emerging markets Financial Chronicle, 2 months ago Angel Broking remains neutral on Lupin MyIris, 2 months ago
BENGALURU: India's fifth-largest IT services company Tech Mahindra said it will acquire Virginia, US-based Lightbridge Communications Corporation (LCC) for $240 million (over Rs 1,400 crore), making it the largest overseas acquisition it has ever ...Times of India, 1 week ago TechM buys US network services firm for $240m The Financial Chronicle, 1 week ago Tech Mahindra : acquires US company for $240m 4 Traders, 6 days ago
— By | Nov 21, 2014 01:09 am With An Annual Revenue Of About $430 Mn, Lightbridge Communications Will Help The Country's Fifth-Largest Software Services Firm Strengthen Its Presence In The Fast-Growing Telecom And Enterprises Network Market New ...The Freepress Journal, 6 days ago Tech Mahindra to buy LCC for $240 mn in largest Indian IT deal this year Samaylive, 6 days ago Tech Mahindra buys US company for 240 million Hindustan Times, 6 days ago Tech Mahindra buys LCC for $240 million in largest Indian IT deal this year DNA India, 1 week ago
More from: , Economic Times...and 1 other sources
Mumbai : Ranbaxy Laboratories , the company in waiting to be merged with Sun Pharma, has taken a legal recourse against the US drug regulator for revoking the tentative approvals granted for launching the generic versions of AstraZeneca's heartburn ...4 Traders, 1 week ago Ranbaxy files suit against USFDA for revoking approved drugs DNA India, 1 week ago Ranbaxy sues FDA for revoking approvals [DNA : Daily News & Analysis (India)] Pharmacy Choice, 1 week ago Double blow to Ranbaxy Calcutta Telegraph, 3 weeks ago
In a setback, the US court has denied a request by drug-maker Ranbaxy Laboratories to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche€s antiviral Valcyte. Ranbaxy had sought the restraining order against ...MyIris, 1 week ago
For long at the receiving end, Ranbaxy Laboratories Ltd has chosen to go on the offensive against the United States Food and Drug Administration (USFDA), suing the US regulator for revoking tentative approvals given to it six years ago to launch ...Hindu Business Line, 1 week ago Ranbaxy sues USFDA for revoking approvals for 2 drugs; stk down Economic Times, 1 week ago
closed down by 2.45 per cent, wiping out Rs 1,228.13 crore from its market valuation, as the company's September quarter results were "below" market expectations. Cipla fell by 2.93 per cent to Rs 605.85 in day trade before closing at Rs 608.85, ...Business Standard India, 1 week ago Cipla shares fall as second quarter numbers disappoint Business Today India, 1 week ago Cipla shares fall almost 3% post Q2 results Hindu Business Line, 1 week ago
More from: , India TV...and 3 other sources
on your WebpageAdd Widget >Get your members hooked!